Responsiveness of epigenetic aging biomarkers to longevity interventions in humans

Raghav Sehgal and colleagues built TransLAGE, a harmonized database covering 51 public and private longitudinal intervention studies. They calculated 16 prominent epigenetic clocks for each study and added 94 DNA-methylation biomarkers to help interpret clock changes. Clocks trained on mortality risk or pace of aging showed the strongest and most consistent responses across interventions. Pharmacological and lifestyle interventions produced the strongest DNA-methylation responses. Study population and intervention duration affected responsiveness. The analysis also favors explainable clocks with multiple subscores over single-score clocks because the subscores can identify biological processes that move in opposite directions. The work is a methods and evidence-synthesis contribution, not a new randomized trial of one molecule. The fetched PubMed page does not state the participant total, pooled effect sizes, confidence intervals, or p values. It therefore cannot show that any specific supplement or drug extends life. Its immediate value is practical. Trial designers can select clocks and biomarker subsets before recruitment, reduce multiple testing, and avoid treating every change in an epigenetic clock as equivalent. The findings also support caution: clock choice, population, and duration can decide whether an intervention appears biologically active.

Moreover, clocks with multiple subscores (that is 'explainable clocks') provide specificity and greater mechanistic insight into the responsiveness of interventions than single-score clocks. These findings can help to design future clinical trials by guiding the choice of interventions and of specific subsets of DNAm biomarkers to minimize multiple testing, study duration, study population and sample size, with the eventual aim of uncovering DNAm biomarkers that can be used as surrogate aging endpoints.